Ren Hui, Wang Xiaole, Fang Ting, Liu Lang, Zhao Xiaolan, Lv Jingxian, Liu Fushui
Jiangxi University of Chinese Medicine, Nanchang, China.
The Affiliated Hospital of Jiangxi University of Chinese Medicine, Nanchang, China.
Medicine (Baltimore). 2025 Sep 5;104(36):e44299. doi: 10.1097/MD.0000000000044299.
As a minimally invasive technique, Fu's subcutaneous needling (FSN) has been widely adopted in Chinese clinical practice for managing neck-type cervical spondylosis (CS). However, current evidence regarding its therapeutic efficacy remains inconclusive due to methodological limitations in existing studies. This systematic review and meta-analysis therefore sought to quantitatively synthesize available randomized controlled trials to evaluate the clinical effectiveness and safety of FSN for this prevalent musculoskeletal disorder.
This study protocol was prospectively registered in PROSPERO (Registration ID: CRD420251036627). The databases searched include PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure, Wanfang Data Knowledge Service Platform (Wanfang), VIP Database (VIP), and China Biology Medicine disc (CBM). A comprehensive search was conducted across the 8 electronic databases from their inception through April 18, 2025. Eligible studies included randomized controlled trials comparing FSN with non-FSN therapies for neck-type CS.
This study included 10 clinical studies with a total of 696 patients suffering from neck-type CS. The results of the meta - analysis revealed that the experimental group had significant advantages over the control group in terms of clinical efficacy. Specifically, for the total effective rate (odds ratio = 5.45, 95% confidence intervals [CI] = [2.75, 10.81], Z = 4.85, P < .00001), cure rate (odds ratio = 2.25, 95% CI = [1.51, 3.34], Z = 4.01, P < .00001), visual analogue scale score (VAS, mean difference = -1.21, 95% CI = [-1.30, -1.12], Z = 25.10, P < .00001), and Neck Disability Index score (NDI, mean difference = -1.33, 95% CI = [-1.92, -0.75], Z = 4.48, P < .00001), the experimental group outperformed the control group.
This study indicates that FSN is a safe and effective strategy for managing neck-type CS. Therefore, it can be considered as a common clinical treatment modality for neck-type CS.
浮针作为一种微创技术,已在中国临床实践中广泛应用于治疗颈型颈椎病(CS)。然而,由于现有研究的方法学局限性,关于其治疗效果的当前证据仍不确凿。因此,本系统评价和荟萃分析旨在定量综合现有随机对照试验,以评估浮针治疗这种常见肌肉骨骼疾病的临床有效性和安全性。
本研究方案已在国际前瞻性系统评价注册库(PROSPERO)中进行前瞻性注册(注册号:CRD420251036627)。检索的数据库包括PubMed、Embase、Cochrane图书馆、Web of Science、中国知网、万方数据知识服务平台(万方)、维普数据库(维普)和中国生物医学文献数据库(CBM)。对这8个电子数据库从建库至2025年4月18日进行全面检索。符合条件的研究包括比较浮针与非浮针疗法治疗颈型CS的随机对照试验。
本研究纳入了10项临床研究,共有696例颈型CS患者。荟萃分析结果显示,试验组在临床疗效方面显著优于对照组。具体而言,在总有效率(比值比=5.45,95%置信区间[CI]=[2.75, 10.81],Z=4.85,P<.00001)、治愈率(比值比=2.25,95%CI=[1.51, 3.34],Z=4.01,P<.00001)、视觉模拟量表评分(VAS,平均差值=-1.21,95%CI=[-1.30, -1.12],Z=25.10,P<.00001)和颈部功能障碍指数评分(NDI,平均差值=-1.33,95%CI=[-1.92, -0.75],Z=4.48,P<.00001)方面,试验组均优于对照组。
本研究表明浮针是治疗颈型CS的一种安全有效的策略。因此,可将其视为颈型CS的一种常用临床治疗方式。